DongKook Pharmaceutical Co., Ltd.

KOSDAQ:A086450 Stock Report

Market Cap: ₩767.7b

DongKook Pharmaceutical Valuation

Is A086450 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A086450 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A086450 (₩17460) is trading above our estimate of fair value (₩4766.95)

Significantly Below Fair Value: A086450 is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for A086450?

Key metric: As A086450 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for A086450. This is calculated by dividing A086450's market cap by their current earnings.
What is A086450's PE Ratio?
PE Ratio14.1x
Earnings₩54.48b
Market Cap₩767.69b

Price to Earnings Ratio vs Peers

How does A086450's PE Ratio compare to its peers?

The above table shows the PE ratio for A086450 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average15.3x
A003090 Daewoong
7.2xn/a₩854.6b
A214370 Caregen
30.5x13.6%₩1.1t
A000640 Dong-A Socio Holdings
13.2xn/a₩674.5b
A003850 Boryung
10.3x9.9%₩667.9b
A086450 DongKook Pharmaceutical
14.1x14.4%₩767.7b

Price-To-Earnings vs Peers: A086450 is good value based on its Price-To-Earnings Ratio (14.1x) compared to the peer average (15.3x).


Price to Earnings Ratio vs Industry

How does A086450's PE Ratio compare vs other companies in the KR Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
A007370 Jin Yang Pharmaceutical
2.4xn/aUS$47.51m
No more companies available in this PE range
A086450 14.1xIndustry Avg. 14.2xNo. of Companies8PE01224364860+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: A086450 is good value based on its Price-To-Earnings Ratio (14.1x) compared to the KR Pharmaceuticals industry average (15x).


Price to Earnings Ratio vs Fair Ratio

What is A086450's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A086450 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio14.1x
Fair PE Ratio18.4x

Price-To-Earnings vs Fair Ratio: A086450 is good value based on its Price-To-Earnings Ratio (14.1x) compared to the estimated Fair Price-To-Earnings Ratio (18.4x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies